Skip to main content

and
Your search also matched 26 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

Include preview-only content
  1. Article

    Open Access

    Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

    Fluorescence in situ hybridization evaluation is essential for initial risk stratification in multiple myeloma. While the presence of specific cytogenetic high-risk abnormalities (HRA) is known to confer a poor p...

    M Binder, S V Rajkumar, R P Ketterling, P T Greipp, A Dispenzieri in Blood Cancer Journal (2017)

  2. Article

    Open Access

    Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

    Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone ...

    P Ravi, S Kumar, W Gonsalves, F Buadi, M Q Lacy, R S Go in Blood Cancer Journal (2017)

  3. Article

    Open Access

    Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

    We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) pa...

    N Tandon, S V Rajkumar, B LaPlant, A Pettinger, M Q Lacy in Blood Cancer Journal (2017)

  4. Article

    Open Access

    Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

    We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal prote...

    P Ravi, S Kumar, J T Larsen, W Gonsalves, F Buadi, M Q Lacy, R Go in Blood Cancer Journal (2016)

  5. Article

    Open Access

    Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

    Cytogenetic evaluation at the time of diagnosis is essential for risk stratification in multiple myeloma, however little is known about the occurrence and prognostic significance of cytogenetic evolution durin...

    M Binder, S V Rajkumar, R P Ketterling, A Dispenzieri, M Q Lacy in Blood Cancer Journal (2016)

  6. Article

    Open Access

    Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

    Importance of interphase fluorescent in situ hybridization (FISH) with cytoplasmic staining of immunoglobulin FISH (cIg-FISH) on bone marrow is not well understood in light chain amyloidosis (AL). This is in cont...

    R Warsame, S K Kumar, M A Gertz, M Q Lacy, F K Buadi, S R Hayman in Blood Cancer Journal (2015)

  7. Article

    Open Access

    Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

    Renal impairment (RI) is seen in over a quarter of patients with newly diagnosed multiple myeloma (NDMM). It is not clear if reversal of RI improves the outcome to that expected for NDMM patients without RI. W...

    W I Gonsalves, N Leung, S V Rajkumar, A Dispenzieri, M Q Lacy in Blood Cancer Journal (2015)